ASX:NEUPharmaceuticals
Assessing Neuren Pharmaceuticals (ASX:NEU) Valuation After Its Latest Annual Earnings Reset
Earnings trigger and why Neuren is on radar
Neuren Pharmaceuticals (ASX:NEU) has come into focus after releasing its full year 2025 results, reporting revenue of A$84.84 million and net income of A$30.44 million, both lower than the prior year.
See our latest analysis for Neuren Pharmaceuticals.
The share price reaction has been sharp, with a 1 day share price return of an 8.79% decline and a 30 day share price return of a 24.75% decline. The 1 year total shareholder return of 1.87% and 3...